Cell-Bound Complement Biomarkers for Systemic Lupus Erythematosus: From Benchtop to Bedside

Rheumatic Disease Clinics of North America

Volumn 36, Issue 1, 2010, Pages 161-172

  Liu, Chau Ching ^a   Manzi, Susan ^a,b   Kao, Amy H ^a   Navratil, Jeannine S ^a   Ahearn, Joseph M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomarkers; Cell bound complement activation products; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; DOUBLE STRANDED DNA ANTIBODY;

CARDIOVASCULAR RISK; CELL ADHESION; COMPLEMENT SYSTEM; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE COURSE; ERYTHROCYTE; HUMAN; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOLOGICAL MARKERS; BLOOD CELLS; COMPLEMENT ACTIVATION; COMPLEMENT C3D; COMPLEMENT C4B; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDE FRAGMENTS; PHENOTYPE;

EID: 77349113577     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.12.003     Document Type: Review

References (40)

1. Sherer Y., Gorstein A., Fritzler M.J., et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34 2 (2004) 501-537
2. Rahman A., and Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 358 9 (2008) 929-939
3. Tan E.M., Cohen A.S., and Fries J.F. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
4. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725
5. Bombardier C., Gladman D.D., Urowitz M.B., et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 (1992) 630-640
6. Liang M.H., Socher S.A., Larson M.G., et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32 (1989) 1107-1118
7. Bae S.C., Koh H.K., Chang D.K., et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 10 6 (2001) 405-409
8. Hay E.M., Bacon P.A., Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM 86 7 (1993) 447-458
9. Vaughan J.H., Bayles T.B., and Favour C.B. The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone (ACTH) therapy in lupus erythematosus disseminatus. J Lab Clin Med 37 (1951) 698-702
10. Schur P.H., and Sandson J. Immunological factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278 (1968) 533-538
11. Cook H.T., and Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2 6 (2006) 330-337
12. Muller-Eberhard H.J. Molecular organization and function of the complement system. Annu rev Biochem 57 (1988) 321-347
13. Liszewski M.K., Farries T.C., Lublin D.M., et al. Control of the complement system. Adv Immunol 61 (1996) 201-283
14. Walport M.J. Complement. First of two parts. N Engl J Med 344 (2001) 1058-1066
15. Law S.K., and Levine R.P. Interaction between the third complement component and cell surface macromolecules. Proc Natl Acad Sci U S A 74 (1977) 2701
16. Law S.K.A. The covalent binding reaction of C3 and C4. Ann N Y Acad Sci 421 (1983) 246-258
17. Lloyd W., and Schur P.H. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine 60 (1981) 208-217
18. Valentijn R.M., van Overhagen H., Hazevoet H.M., et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 28 (1985) 904-913
19. Ricker D.M., Hebert L.A., Rohde R., et al. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 slevels. Am J Kidney Dis 19 (1991) 678-685
20. Swaak A.J., Groenwold J., and Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45 (1986) 359-366
21. Abrass C.K., Nies K.M., Louie J.S., et al. Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 23 (1980) 273-282
22. Liu C.-C., Ahearn J.M., and Manzi S. Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future. Curr Rheumatol Rep 6 (2004) 85-88
23. Liu C.C., Manzi S., Danchenko N., et al. New advances in measurement of complement activation: lessons of systemic lupus erythematosus. Curr Rheumatol Rep 6 5 (2004) 375-381
24. Sturfelt G., Jonasson L., and Sjoholm A.G. Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol 14 (1985) 184-196
25. Hopkins P., Belmont H.M., Buyon J.P., et al. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31 (1988) 632-641
26. Wild G., Watkins J., Ward A.M., et al. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol 80 (1990) 167-170
27. Porcel J.M., Ordi J., Castro-Salomo A., et al. The value of complement activation products in the assessment of systmeic lupus erythematosus flares. Clin Immunol Immunopathol 74 (1995) 283-288
28. Manzi S., Rairie J.E., Carpenter A.B., et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39 (1996) 1178-1188
29. Buyon J.P., Tamerius J., Belmont H.M., et al. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 35 (1992) 1028-1037
30. Tieley C.A., Romans D.G., and Crookston M.C. Localization of Chido and Rodgers determinants to the C4d fragment of human C4. Nature 276 (1978) 713-715
31. Atkinson J.P., Chan A.C., Karp D.R., et al. Origin of the fourth component of complement related Chido and Rodgers blood group antigens. Complement 5 (1988) 65-76
32. Manzi S., Navratil J.S., Ruffing M.J., et al. Measurement of erythrocyte C4d and complement receptor 1 in the diagnosis of systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3596-3604
33. Liu C.C., Manzi S., Kao A.H., et al. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus eryhematosus. Arthritis Rheum 52 (2005) 3087-3099
34. Navratil J.S., Manzi S., Kao A.H., et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 54 2 (2006) 670-674
35. Liu C.C., Kao A.H., Hawkins D.M., et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci 2 4 (2009) 300-308
36. Solomon D.H., Kavanaugh A.J., and Schur P.H. American College of Rheumatology Ad Hoc Committee on Immunologic Testing G. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47 4 (2002) 434-444
37. Slater C.A., Davis R.B., and Shmerling R.H. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med 156 13 (1996) 1421-1425
38. Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum, in press.
39. Rennie C.M., Thompson S., Parker A.C., et al. Human erythrocyte fractionation in Percoll density gradients. Clin Chim Acta 98 (1979) 119-125
40. Piomelli S., and Seaman C. Mechanism of red blood cell aging: relationship of cell density and cell age. Am J Hematol 42 (1992) 46-52